ZyVersa Therapeutics Inc. (ZVSA)
0.60
0.01 (2.13%)
At close: Apr 02, 2025, 3:58 PM
0.61
1.90%
After-hours: Apr 02, 2025, 07:50 PM EDT
2.13% (1D)
| Bid | 0.56 |
| Market Cap | 1.53M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -8.48 |
| PE Ratio (ttm) | -0.07 |
| Forward PE | -0.29 |
| Analyst | Strong Buy |
| Ask | 0.64 |
| Volume | 59,017 |
| Avg. Volume (20D) | 866,168 |
| Open | 0.59 |
| Previous Close | 0.59 |
| Day's Range | 0.58 - 0.61 |
| 52-Week Range | 0.58 - 8.05 |
| Beta | 0.68 |
About ZVSA
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, In...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 11, 2022
Employees 7
Stock Exchange NASDAQ
Ticker Symbol ZVSA
Website https://www.zyversa.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ZVSA stock is "Strong Buy." The 12-month stock price forecast is $240, which is an increase of 40060.64% from the latest price.
Stock Forecasts4 months ago
+39.56%
ZyVersa Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
11 months ago
+15.63%
ZyVersa Therapeutics shares are trading higher after the company announced the publication of a scientific paper in a peer-reviewed journal that reinforces the rationale for inhibiting ASC with IC 100 to potentially attenuate cardiac comorbidities in patients with Alzheimer's Disease.
